CDEK
← All drugs Report issue

belzupacap sarotalocan

Small moleculeexperimental

Clinical trial activity

5 trials · 1 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0

Earliest trial started Feb 27, 2017 (NCT03052127)

Timeline

2010s

  1. Jan 1, 2017

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2020

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Heparan Sulphate ProteoglycansBINDING AGENT

    Heparan Sulphate Proteoglycans binding agent

    Following cell death, damage-associated molecular patterns are released and an immune response is triggered.

  • Cell membraneDISRUPTING AGENT

    Cell membrane disrupting agent

    Following cell death, damage-associated molecular patterns are released and an immune response is triggered.

  • Oncolytic virusOTHER

    Oncolytic virus other

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • au-011

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06643884Phase 2Oct 25, 2024Aura Biosciences
NCT06007690Phase 3Sep 30, 2023Aura Biosciences
NCT05483868Phase 1Sep 26, 2022Aura Biosciences
NCT04417530Phase 2Jul 1, 2020Aura Biosciences
NCT03052127Phase 1Feb 27, 2017Aura Biosciences
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Aura BiosciencesFor profit5532017
1 organizations
Page 1 / 1